Singular Genomics Systems, Inc. (OMIC)
$
20.01
Key metrics
Financial statements
Free cash flow per share
-32.3283
Market cap
50.8 Million
Price to sales ratio
19.0419
Debt to equity
0.4097
Current ratio
7.3718
Income quality
0.9318
Average inventory
12.4 Million
ROE
-0.5787
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Singular Genomics Systems, Inc., a life science technology company, is focused on developing next-generation sequencing and multiomics technology to create products that support researchers and clinicians in advancing science and medicine. The company reported a net loss of -$94,820,000.00 indicating challenges in its operations. However, it also reported an income before tax of -$94,820,000.00 showcasing its pre-tax profitability. The total costs and expenses for the company are ${{ 105,712,000.00 reflecting its overall spending. The net income ratio is -32.57 providing insight into the company's profitability margin. Additionally, the weighted average number of shares outstanding is 2,426,541.00 highlighting the company's shareholder base. Singular Genomics manufactures the G4 Instrument, a benchtop next-generation sequencer that generates genetic sequencing results alongside a menu of consumable kits. The PX Integrated Solution is another offering, integrating single-cell analysis, spatial analysis, genomics, and proteomics into one versatile multiomics instrument. The company has established partnerships with prominent organizations such as Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4. Furthermore, a collaboration with the Broad Institute of MIT and Harvard connects the G4 to the Terra platform, a data management platform. Incorporated in 2016, Singular Genomics is headquartered in La Jolla, California. The current stock of Singular Genomics is affordable at $20.01 making it suitable for budget-conscious investors. Despite the potential for growth, the stock has a low average trading volume of 13,411.00 indicating lower market activity. With a market capitalization of $50,765,770.00 the company is classified as a small-cap player. It is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth.
What is Singular Genomics Systems, Inc. (OMIC)'s stock forecast?
Analysts predict Singular Genomics Systems, Inc. stock to fluctuate between $5.34 (low) and $23.41 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Singular Genomics Systems, Inc.'s market capitalization?
As of 2025-02-20, Singular Genomics Systems, Inc.'s market cap is $50,765,770, based on 2,537,020 outstanding shares.
How does Singular Genomics Systems, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Singular Genomics Systems, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Singular Genomics Systems, Inc. (OMIC) stock?
To buy Singular Genomics Systems, Inc. (OMIC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for OMIC. Place an order (Market, Limit, etc.).
What is the best time to invest in Singular Genomics Systems, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Singular Genomics Systems, Inc. stock ever split?
Singular Genomics Systems, Inc.'s last stock split was 1:30 on 2024-06-26.
How did Singular Genomics Systems, Inc. perform in the last earnings report?
Revenue: $2,911,000 | EPS: -$39.08 | Growth: 5.00%.
Where can I find Singular Genomics Systems, Inc.'s investor relations reports?
Visit https://singulargenomics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Singular Genomics Systems, Inc.?
You can explore historical data from here
What is the all-time high and low for Singular Genomics Systems, Inc. stock?
All-time high: $1,001.10 (2021-06-02) | All-time low: $5.34 (2024-09-11).
What are the key trends affecting Singular Genomics Systems, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
4 months ago
SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
prnewswire.com
5 months ago
LOS ANGELES , Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ: OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
accessnewswire.com
5 months ago
LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.
See all news
